A traditional Chinese medicine composition for transporting the spleen, removing turbidity, detoxifying and resolving stasis and application thereof

By using a combination of traditional Chinese medicines including Smilax glabra, Dioscorea hypoglauca, corn silk, stir-fried Coix lacryma-jobi, Coptis chinensis, and Curcuma longa, a decoction was prepared, which solved the problem of unclear compound prescriptions in traditional Chinese medicine. This resulted in significant effects of lowering uric acid, improving liver and kidney function, and anti-inflammatory and analgesic effects, and is suitable for the treatment of gout and hyperuricemia.

CN122424281APending Publication Date: 2026-07-21ZHEJIANG CHINESE MEDICAL UNIVERSITY
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202610849252.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-06-12
Publication Date
2026-07-21

AI Technical Summary

Technical Problem

The lack of clear formulas, standardized experimental verification, and standardized preparation methods in existing traditional Chinese medicine prescriptions limits the application of traditional Chinese medicine compound prescriptions in the treatment of gout and hyperuricemia. In addition, existing Western medicines have problems such as obvious side effects, insufficient safety with long-term use, and large differences in individual efficacy.

Method used

Using Smilax glabra, Dioscorea hypoglauca, corn silk, stir-fried Coix lacryma-jobi, Coptis chinensis, and Curcuma longa as the main raw materials, a traditional Chinese medicine composition is prepared by decoction. It is used to prevent or treat gout and hyperuricemia, significantly reduce uric acid levels, alleviate inflammatory response, and protect liver and kidney function.

Benefits of technology

It significantly reduces uric acid levels, improves liver and kidney function indicators, reduces inflammatory factor levels, alleviates joint swelling, and increases pain threshold, demonstrating excellent anti-inflammatory and analgesic effects. It is also highly safe and suitable for long-term intervention.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122424281A_ABST
    Figure CN122424281A_ABST
Patent Text Reader

Abstract

The application relates to the technical field of traditional Chinese medicine compound, in particular to a traditional Chinese medicine composition, a traditional Chinese medicine preparation, a preparation method thereof and application of the traditional Chinese medicine composition in medicines for preventing and / or treating gout and / or hyperuricemia. The traditional Chinese medicine composition comprises the following raw materials or consists of the following raw materials: smilax glabra, yam, corn silk, fried coix seed, goldthread and turmeric. The spleen-regulating, phlegm-dissolving and blood-activating traditional Chinese medicine composition prepared by decoction can significantly reduce uric acid in animal experiments, effectively reduce creatinine (CREA), blood urea nitrogen (BUN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, simultaneously reduce inflammatory reactions and reduce serum inflammatory factors IL-1beta, IL-6, IFN-gamma and IL-17A levels. The application can also significantly improve gout model mouse paw pad swelling, improve pain threshold and has a protective effect on liver and kidney functions.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This application relates to the field of traditional Chinese medicine compound technology, specifically to a traditional Chinese medicine composition, a traditional Chinese medicine preparation, a method for preparing the same, and its use in a medicament for the prevention and / or treatment of gout and / or hyperuricemia. Background Technology

[0002] Gout and hyperuricemia are common metabolic diseases characterized by disordered uric acid metabolism, leading to elevated blood uric acid levels and triggering joint inflammation. Long-term hyperuricemia can also cause complications such as kidney damage and cardiovascular disease, severely impacting patients' quality of life. Current clinical treatment mainly includes three classes of drugs: those that inhibit uric acid production (such as allopurinol), those that promote uric acid excretion, and anti-inflammatory and analgesic drugs. However, these drugs generally suffer from significant side effects, insufficient safety profiles with long-term use, and large individual variability in efficacy.

[0003] Traditional Chinese medicine (TCM) compound formulas, due to their multi-target regulation, holistic conditioning, and relatively high safety, show promising application prospects in the treatment of gout and hyperuricemia. However, existing TCM regimens often lack clearly defined formulas, standardized experimental verification, and standardized preparation methods, which limits their further promotion and application.

[0004] Therefore, there is an urgent need to develop a traditional Chinese medicine composition with a clear formula, stable preparation method and good efficacy for the prevention or treatment of gout and hyperuricemia. Summary of the Invention

[0005] The present invention aims to at least partially solve one of the technical problems in the related art.

[0006] Therefore, an embodiment of the first aspect of the present invention provides a traditional Chinese medicine composition comprising or composed of the following raw materials: Smilax glabra, Dioscorea hypoglauca, corn silk, stir-fried Coix lacryma-jobi, Coptis chinensis, and Curcuma longa. The spleen-invigorating, turbidity-eliminating, and blood-activating traditional Chinese medicine composition described in this embodiment of the invention can be obtained by decoction. In animal experiments, it has shown a significant uric acid-lowering effect and can effectively reduce creatinine (CREA), blood urea nitrogen (BUN), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels, while simultaneously alleviating inflammatory responses and reducing serum levels of inflammatory factors IL-1β, IL-6, IFN-γ, and IL-17A. This invention can also significantly improve paw pad swelling and increase the pain threshold in gout model mice, and has a protective effect on liver and kidney function.

[0007] In some embodiments, the raw materials constitute the traditional Chinese medicine composition in the following parts by weight:

[0008] 10–20 parts of Smilax glabra; Dioscorea hypoglauca 6–15 parts; 3–10 parts corn silk; 10–20 servings of stir-fried Job's tears; Coptis chinensis 3–10 parts; and Turmeric 6–15 parts.

[0009] In some embodiments, the raw materials constitute the traditional Chinese medicine composition in the following parts by weight: 12 parts of Smilax glabra, 9 parts of Dioscorea hypoglauca, 6 parts of corn silk, 12 parts of stir-fried Coix lacryma-jobi, 6 parts of Coptis chinensis, and 9 parts of Curcuma longa.

[0010] An embodiment of the present invention provides a traditional Chinese medicine preparation comprising: The raw material is a raw medicinal powder or its aqueous or organic solvent extract as the active ingredient; and Pharmaceutically acceptable excipients. The ingredients mentioned include Smilax glabra, Dioscorea hypoglauca, corn silk, stir-fried Coix lacryma-jobi, Coptis chinensis, and Curcuma longa, or a combination thereof.

[0011] In some embodiments, the raw materials are composed of the following parts by weight: 10–20 parts of Smilax glabra; Dioscorea hypoglauca 6–15 parts; 3–10 parts corn silk; 10–20 servings of stir-fried Job's tears; Coptis chinensis 3–10 parts; and Turmeric 6–15 parts.

[0012] In some embodiments, the raw materials are composed of the following parts by weight: 12 parts of Smilax glabra, 9 parts of Dioscorea hypoglauca, 6 parts of corn silk, 12 parts of stir-fried Coix lacryma-jobi, 6 parts of Coptis chinensis, and 9 parts of Curcuma longa.

[0013] In some embodiments, the formulation is a tablet, capsule, pill, granule, or oral liquid.

[0014] A third aspect of the present invention provides a method for preparing a traditional Chinese medicine preparation as described in the first aspect of the present invention, comprising: Add water to the traditional Chinese medicine composition as described in the first aspect of the present invention and decoct it, wherein the decoction includes heating over high heat for 40 minutes and then simmering over low heat for 40 minutes. The decoction obtained after boiling is concentrated to obtain a traditional Chinese medicine extract, which is used as the traditional Chinese medicine preparation.

[0015] Optionally, each portion of the traditional Chinese medicine composition contains 54 g of the total amount, and the volume of the traditional Chinese medicine extract obtained after concentration is approximately 76.9 mL.

[0016] Use of the traditional Chinese medicine composition as described in the embodiments of the first aspect of the present invention or the traditional Chinese medicine preparation as described in the embodiments of the second aspect of the present invention in the preparation of a medicament for the prevention and / or treatment of gout and / or hyperuricemia.

[0017] In some embodiments, the traditional Chinese medicine composition or preparation improves at least one of the following indicators: Lower CREAM and BUN levels; Lower ALT and AST levels; Reduces the levels of inflammatory factors IL-1β, IL-6, IFN-γ, and IL-17A; Reduce joint swelling; and Increase pain threshold.

[0018] The advantages and technical effects brought about by the independent claims according to the embodiments of the present invention are as follows: (1) The traditional Chinese medicine composition described in the embodiments of the present invention can significantly reduce blood uric acid levels, while significantly improving liver and kidney function indicators and reducing the levels of inflammatory factors such as IL-6 and IL-17A; and shows excellent anti-inflammatory and analgesic effects in terms of improving foot swelling and pain threshold.

[0019] (2) The traditional Chinese medicine composition described in the embodiments of the present invention contains only 6 kinds of traditional Chinese medicine. Compared with related technologies, the formulation is simpler, but the efficacy is not reduced or even better.

[0020] (3) The traditional Chinese medicine composition described in the embodiments of the present invention has a multi-target synergistic effect, high safety, and is suitable for long-term intervention and treatment. Attached Figure Description

[0021] Figure 1 The figure shows the comparison of serum uric acid, serum creatinine, blood urea nitrogen, alanine aminotransferase and aspartate aminotransferase levels in the blood of gout model mice, gout model control mice and blank control mice after treatment with the spleen-tonifying and blood-activating formula group, the turbidity-removing and pain-relieving formula group and the allopurinol group according to embodiments of the present invention.

[0022] Figure 2 Anatomical diagrams of the spleen, kidneys, and liver of gout model mice, gout model control mice, and blank control mice after treatment with the spleen-tonifying and blood-activating formula group, the turbidity-removing and pain-relieving formula group, and the allopurinol group according to embodiments of the present invention are shown.

[0023] Figure 3 The figure shows a comparison of the paw pad swelling index of gout model mice, gout model control mice, and blank control mice after treatment with the spleen-tonifying, turbidity-eliminating, blood-activating, and dampness-removing formula group, the turbidity-removing and pain-relieving formula group, and the allopurinol group according to embodiments of the present invention.

[0024] Figure 4 The figure shows the comparison of the levels of inflammatory factors in the blood of gout model mice, gout model control mice, and blank control mice after treatment with the spleen-tonifying, turbidity-eliminating, blood-activating, and dampness-removing formula group, the turbidity-removing and pain-relieving formula group, and the allopurinol group according to embodiments of the present invention. Detailed Implementation

[0025] Embodiments of the present invention are described in detail below, examples of which are illustrated in the accompanying drawings. The embodiments described below with reference to the accompanying drawings are exemplary and intended to explain the present invention, and should not be construed as limiting the present invention.

[0026] This invention is based on the inventor's discoveries and understanding of the following facts and problems: Gout and hyperuricemia are increasingly serious metabolic diseases worldwide. Their core pathological mechanism is an imbalance in uric acid metabolism, leading to abnormally high blood uric acid levels. Hyperuricemia is not only a prerequisite for gout attacks but can also induce various complications such as kidney stones, kidney damage, and cardiovascular disease, severely impacting patients' quality of life and even threatening their lives. With changes in dietary structure (such as increased intake of high-purine foods) and lifestyle, the incidence of gout and hyperuricemia is rising year by year and showing a trend towards affecting younger people, becoming a significant public health issue. Therefore, developing safe and effective methods for the prevention and treatment of gout and hyperuricemia is of great practical significance and clinical value for improving patients' health and reducing the social medical burden.

[0027] Furthermore, hyperuricemia refers to a metabolic abnormality where fasting blood uric acid levels on two separate occasions exceed 420 μmol / L for men and 360 μmol / L for women. When blood uric acid exceeds its saturation point in the blood or tissues, sodium urate crystals form and deposit in joints and other areas, inducing local inflammation and tissue damage, i.e., a gout attack. Clinical studies and treatment guidelines have confirmed that drugs used to treat hyperuricemia (HUA) can lower blood uric acid levels, thereby inhibiting gout attacks at their source and dissolving tophi. Therefore, uric acid-lowering drugs suitable for HUA can also be used to treat gout. For example, urate transporter 1 (URAT1) inhibitors such as deuterotenolé and allopurinol, a drug that inhibits uric acid synthesis, have been proven in clinical trials to effectively reduce serum uric acid levels, decrease the frequency of gout attacks, and even dissolve tophi in gout patients. Uric acid oxidase drugs treat HUA by promoting uric acid breakdown and can also significantly improve 15 clinical symptoms in gout patients. Currently, the technologies and drugs used clinically to treat gout and / or hyperuricemia are mainly divided into three categories: First, drugs that inhibit uric acid production, such as allopurinol and febuxostat. Their advantage lies in reducing uric acid production from the source, with a clear uric acid-lowering effect, and are suitable for patients with excessive uric acid production. However, these drugs have certain side effects. Allopurinol may cause severe skin allergic reactions, while febuxostat poses potential risks to the cardiovascular system and requires long-term medication to maintain efficacy. Secondly, there are drugs that promote uric acid excretion, such as benzbromarone and probenecid. Their advantage is that they can rapidly promote the excretion of uric acid through the kidneys, with a relatively quick onset of action. The disadvantages are that they may increase the burden on the kidneys, limiting their applicability to patients with renal insufficiency, and they can easily lead to adverse reactions such as kidney stones. Thirdly, there are symptomatic treatment drugs, such as colchicine and nonsteroidal anti-inflammatory drugs (NSAIDs), mainly used to relieve inflammation and pain during acute gout attacks. Their advantages are rapid onset of action and significant analgesic and anti-inflammatory effects; however, these drugs cannot lower blood uric acid levels and cannot fundamentally treat the disease. Furthermore, long-term use can easily cause side effects such as gastrointestinal irritation and liver and kidney damage. In addition, existing drug treatments all suffer from significant individual differences and poor efficacy in some patients, making it difficult to meet the diverse treatment needs of clinical practice.

[0028] Currently, clinical treatment mainly involves three classes of drugs: drugs that inhibit uric acid production (such as allopurinol), drugs that promote uric acid excretion, and anti-inflammatory and analgesic drugs. However, these drugs generally have significant side effects, insufficient safety with long-term use, and large individual differences in efficacy.

[0029] Traditional Chinese medicine (TCM) compound formulas, due to their multi-target regulation, holistic conditioning, and relatively high safety, show promising application prospects in the treatment of gout and hyperuricemia. However, existing TCM regimens often lack clearly defined formulas, standardized experimental verification, and standardized preparation methods, which limits their further promotion and application.

[0030] Among the related technologies, the "Clearing Turbidity and Relieving Pain Formula" contains Smilax glabra, Dioscorea hypoglauca, corn silk, Coix lacryma-jobi, Siegesbeckia orientalis, Curcuma longa, Taxillus chinensis, Corydalis yanhusuo, and Citrus medica. It is a traditional Chinese medicine compound that has been proven to have a good therapeutic effect on gout. It may effectively relieve gouty arthritis by regulating butyrate metabolism and reshaping macrophage polarization. However, this formula contains nine herbs, and the prescription needs to be simplified. Moreover, the required dosage for the same body weight is high, which poses a potential risk of liver and kidney damage (Song S, Wen X, Chen F, Li J, Shi K, Lou Y, Xu A, Wen C, Shao T. Qu-zhuo-tong-bi decoction exerts goutyarthritis therapy by skewing macrophage polarization through butanoatemetabolism. Chin Med. 2025 Jul 22;20(1):115. doi: 10.1186 / s13020-025-01162-6.PMID: 40696369; PMCID: PMC12281712.).

[0031] Furthermore, while the related patent for Quzhuo Tongbi Granules (CN101884749B) shows 40-80 parts of Smilax glabra, 20-40 parts of Coix lacryma-jobi, 12-28 parts of Paeonia lactiflora, and 3-7 parts of corn silk, this application significantly reduces the amount of Smilax glabra, the principal ingredient, compared to the related technology. This mitigates the spleen and stomach deficiency or liver and kidney dysfunction that can result from excessive or long-term use of Smilax glabra. Moreover, by adjusting the types or proportions of the adjuvant herbs, a rebalancing of the principal, assistant, and adjuvant herbs is achieved. Even with the reduced dosage of Smilax glabra, the overall formula's core effects of anti-gout, anti-inflammatory, and immune-regulating are still superior to the related technology, and it exhibits significant advantages in terms of liver and kidney function damage.

[0032] Therefore, there is an urgent need to develop a traditional Chinese medicine composition with a clear and simplified formula, a stable preparation method, and good efficacy for the prevention or treatment of gout and hyperuricemia.

[0033] An embodiment of the first aspect of the present invention provides a traditional Chinese medicine composition comprising or composed of the following raw materials: Smilax glabra, Dioscorea hypoglauca, corn silk, stir-fried Coix lacryma-jobi, Coptis chinensis, and Curcuma longa.

[0034] In some embodiments, the raw materials constitute the traditional Chinese medicine composition in the following parts by weight: 10–20 parts of Smilax glabra; Dioscorea hypoglauca 6–15 parts; 3–10 parts corn silk; 10–20 servings of stir-fried Job's tears; Coptis chinensis 3–10 parts; and Turmeric 6–15 parts.

[0035] The spleen-invigorating, turbidity-eliminating, and blood-activating traditional Chinese medicine composition provided by this invention can be prepared by decoction. In animal experiments, it has shown a significant uric acid-lowering effect and can effectively reduce creatinine (CREA), blood urea nitrogen (BUN), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels. Simultaneously, it alleviates inflammatory responses and reduces serum levels of inflammatory factors IL-1β, IL-6, IFN-γ, and IL-17A. This invention can also significantly improve paw pad swelling and increase the pain threshold in gout model mice, and has a protective effect on liver and kidney function.

[0036] In some embodiments, the raw materials constitute the traditional Chinese medicine composition in the following parts by weight: 12 parts of Smilax glabra, 9 parts of Dioscorea hypoglauca, 6 parts of corn silk, 12 parts of stir-fried Coix lacryma-jobi, 6 parts of Coptis chinensis, and 9 parts of Curcuma longa.

[0037] An embodiment of the present invention provides a traditional Chinese medicine preparation comprising: The raw material is a raw medicinal powder or its aqueous or organic solvent extract as the active ingredient; and Pharmaceutically acceptable excipients. The ingredients mentioned include Smilax glabra, Dioscorea hypoglauca, corn silk, stir-fried Coix lacryma-jobi, Coptis chinensis, and Curcuma longa, or a combination thereof.

[0038] In some embodiments, the raw materials are composed of the following parts by weight: 10–20 parts of Smilax glabra; Dioscorea hypoglauca 6–15 parts; 3–10 parts corn silk; 10–20 servings of stir-fried Job's tears; Coptis chinensis 3–10 parts; and Turmeric 6–15 parts.

[0039] In some embodiments, the raw materials are composed of the following parts by weight: 12 parts of Smilax glabra, 9 parts of Dioscorea hypoglauca, 6 parts of corn silk, 12 parts of stir-fried Coix lacryma-jobi, 6 parts of Coptis chinensis, and 9 parts of Curcuma longa.

[0040] In some embodiments, the formulation is a tablet, capsule, pill, granule, or oral liquid.

[0041] A third aspect of the present invention provides a method for preparing a traditional Chinese medicine preparation as described in the first aspect of the present invention, comprising: Add water to the traditional Chinese medicine composition as described in the first aspect of the present invention and decoct it, wherein the decoction includes heating over high heat for 40 minutes and then simmering over low heat for 40 minutes. The decoction obtained after boiling is concentrated to obtain a traditional Chinese medicine extract, which is used as the traditional Chinese medicine preparation.

[0042] Optionally, each portion of the traditional Chinese medicine composition contains 54 g of the total amount, and the volume of the traditional Chinese medicine extract obtained after concentration is approximately 76.9 mL.

[0043] Use of the traditional Chinese medicine composition as described in the embodiments of the first aspect of the present invention or the traditional Chinese medicine preparation as described in the embodiments of the second aspect of the present invention in the preparation of a medicament for the prevention and / or treatment of gout and / or hyperuricemia.

[0044] In some embodiments, the traditional Chinese medicine composition or preparation improves at least one of the following indicators: Lower CREAM and BUN levels; Lower ALT and AST levels; Reduces the levels of inflammatory factors IL-1β, IL-6, IFN-γ, and IL-17A; Reduce joint swelling; and Increase pain threshold.

[0045] In this application, the term "comprising / including" is an open-ended expression, meaning it includes the contents specified in this invention, but does not exclude other aspects.

[0046] In this document, the term "pharmaceutically acceptable" refers to compounds, raw materials, compositions, and / or dosage forms that, within the bounds of reasonable medical judgment, are suitable for contact with patient tissues without excessive toxicity, irritation, allergic reactions, or other problems and complications commensurate with a reasonable benefit / risk ratio, and are effective for their intended use.

[0047] In this document, the term "pharmaceutical composition" (or traditional Chinese medicine composition) refers to the compositions of the present invention and formulations of media generally accepted in the art for delivering bioactive compounds to mammals (e.g., humans). Such media include all pharmaceutically acceptable carriers, diluents, or excipients.

[0048] In this article, the term "disease" generally refers to a disease, event, or change in health status. A change in health status may be associated with a specific disease or event, in which case the change may occur concurrently with or prior to the disease or event. Where the change in health status occurs prior to the disease or event, the change in health status may serve as a predictor of the disease or event. For example, a change in health status may be an alteration in the expression level of a specific gene associated with a disease or event. Alternatively, a change in health status may be unrelated to a specific disease or event.

[0049] In this article, the term “treatment” generally refers to preventing a condition or event, slowing the onset or progression of a condition or delaying the occurrence of an event, reducing the risk of developing a condition or experiencing an event, preventing or delaying the development of symptoms associated with a condition or event, reducing or terminating symptoms associated with a condition or event, causing a condition to completely or partially subside, mitigating the severity of a condition or event, or some combination thereof.

[0050] In this paper, the term "effective dose" or "therapeutic effective dose" refers to the dose and time period required to achieve the desired therapeutic outcome. The therapeutically effective dose of a capture agent can vary depending on factors such as an individual's disease state, age, sex, and weight, as well as the capture agent's ability to elicit the desired response in the individual.

[0051] The following embodiments are used to further illustrate the advantages and features of this method, and are not intended to limit the invention. Unless otherwise specified, the experimental methods in the following embodiments are conventional methods, performed according to the techniques or conditions described in the literature in the field or according to the product instructions.

[0052] Unless otherwise specified, all materials and reagents used in the following examples are commercially available. Unless otherwise specified, all quantitative analysis experiments in the following examples were performed in triplicate, and the results were averaged.

[0053] Example Example 1: Preparation of Traditional Chinese Medicine Compound Weigh the raw materials according to the following proportions: Smilax glabra 12 g, Dioscorea hypoglauca 9 g, corn silk 6 g, stir-fried coix seed 12 g, Coptis chinensis 6 g, turmeric 9 g.

[0054] Add an appropriate amount of water and decoct. First, heat over high heat for 40 minutes, then simmer over low heat for 40 minutes. Filter to obtain the decoction, and concentrate it to about 76.9 mL to obtain the compound extract of traditional Chinese medicine.

[0055] For the preparation method of the formula for dispelling turbidity and relieving pain, please refer to the study by Song et al. (2025) described above.

[0056] Example 2: Animal Experiment Verification 2.1 Establishment and Grouping of Experimental Animal Models (1) A gout model was established using mice, which were divided into the following 5 groups, with 8 mice in each group: Blank control group; Gout model group; Traditional Chinese medicine compound treatment group (also known as the spleen-tonifying, turbidity-eliminating, and blood-activating formula group described in the embodiments of this application); The formula for dispelling turbidity and relieving pain; and Allopurinol group.

[0057] Thirty-two Uox-KO mice (purchased from Shanghai Nanmo Co., Ltd.) were used as the gout animal model, and eight wild-type mice (purchased from Shanghai Nanmo Co., Ltd.) were used as the blank control. The sex of the mice was not limited, and their age ranged from 4 to 6 weeks. Before the experiment, the mice were acclimatized in a standard SPF animal room for 7 days, during which they had free access to food and water.

[0058] In the traditional Chinese medicine compound treatment group, the traditional Chinese medicine extract was obtained according to the method described in Example 1 and used for subsequent animal gavage experiments.

[0059] The formula for dispelling turbidity and relieving pain was prepared by obtaining the herbal extract according to the method described in Example 1, and used for subsequent animal gavage experiments.

[0060] The allopurinol group, purchased from Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., product number: National Drug Approval Number H44021492, was used for subsequent animal gavage experiments.

[0061] (2) Administration method The specific administration methods for each group are as follows: The blank control group was treated by gavage with sterile saline to the blank control mouse model once a day, with each mouse receiving 0.2 mL of the drug, for 8 consecutive weeks.

[0062] The gout model group was administered sterile saline by gavage to the gout animal model once a day, with each mouse receiving 0.2 mL of the drug, for 8 consecutive weeks.

[0063] The traditional Chinese medicine compound group was administered to the gout animal model by gavage at a dose of 7.02 g / kg once a day, with each mouse receiving 0.2 mL of the drug, for 8 consecutive weeks.

[0064] The "Quzhuo Tongbi" formula was administered to a gout animal model via gavage at a dose of 18.0 g / kg once daily, with each mouse receiving 0.2 mL of the formula, for a continuous intervention of 8 weeks.

[0065] Allopurinol was administered to a gout animal model at a dose of 3.25 g / kg via gavage once daily, with each mouse receiving 0.2 mL of the drug, for 8 consecutive weeks.

[0066] (3) Detection indicators During the experimental period of this study, the mice were routinely monitored, including assessments of weight changes, behavioral activity, and coat condition. After the experiment, the mice were fasted and deprived of water for 24 hours, and blood samples were collected via the orbital venous plexus sampling method. The collected blood samples were allowed to stand at room temperature for 2 hours, and then centrifuged at 3000 rpm for 15 minutes at 4°C to separate the serum. The separated serum was stored at -80°C and used for the detection of the following biochemical indicators: serum uric acid, CREA, BUN, ALT, AST, inflammatory factors (IL-1β, IL-6, IFN-γ, IL-17A), paw pad swelling index, pain threshold, and liver and kidney indices.

[0067] Specific testing methods The levels of uric acid (S-UA), creatinine (S-CREA), blood urea nitrogen (BUN), alanine aminotransferase (AST), and aspartate aminotransferase (ALT) in the serum of mice in each group were detected using a TBA-40FR fully automated biochemical analyzer.

[0068] The levels of IL-1β (catalog number: EK201BHS-96), IFN-γ (catalog number: EK280HS-96), IL-17A (catalog number: EK217HS-96), and NLRP3 (catalog number: CSB-EL015871MO) in the serum of mice in each group were detected using an enzyme-linked immunosorbent assay (ELISA) kit from Linko Biotechnology Co., Ltd. Specific experimental procedures were performed according to the kit instructions.

[0069] (4) Experimental results The results are as follows Figures 1-4 As shown.

[0070] Figure 1 The figure shows the comparison of serum uric acid, serum creatinine, blood urea nitrogen, alanine aminotransferase and aspartate aminotransferase levels in the blood of gout model mice, gout model control mice and blank control mice after treatment with the spleen-tonifying and blood-activating formula group, the turbidity-removing and pain-relieving formula group and the allopurinol group according to embodiments of the present invention.

[0071] Figure 2 Anatomical diagrams of the spleen, kidneys, and liver of gout model mice, gout model control mice, and blank control mice after treatment with the spleen-tonifying and blood-activating formula group, the turbidity-removing and pain-relieving formula group, and the allopurinol group according to embodiments of the present invention are shown.

[0072] Figure 3The figure shows a comparison of the paw pad swelling index of gout model mice, gout model control mice, and blank control mice after treatment with the spleen-tonifying, turbidity-eliminating, blood-activating, and dampness-removing formula group, the turbidity-removing and pain-relieving formula group, and the allopurinol group according to embodiments of the present invention.

[0073] Figure 4 The figure shows the comparison of the levels of inflammatory factors in the blood of gout model mice, gout model control mice, and blank control mice after treatment with the spleen-tonifying, turbidity-eliminating, blood-activating, and dampness-removing formula group, the turbidity-removing and pain-relieving formula group, and the allopurinol group according to embodiments of the present invention.

[0074] according to Figure 1 It is known that the compound formula (Yunpi Xiezhuo Huoxue Formula) and the Quzhuo Tongbi Formula of the present invention can significantly reduce blood uric acid, with comparable effects, but the dosage when administered is at least half that of the latter.

[0075] according to Figure 1 It can be seen that the serum creatinine, blood urea nitrogen, alanine aminotransferase, and aspartate aminotransferase levels in gout model mice treated with the compound formula (Spleen-Invigorating, Turbidity-Clearing, and Blood-Activating Formula) were all lower than those of the Turbidity-Clearing and Pain-Relieving Formula, demonstrating excellent performance in improving liver and kidney function indicators; according to Figure 2 It can be seen that after treatment with the compound formula of this invention (Yunpi Xiezhuo Huoxue Fang), the splenomegaly, kidney damage and liver enlargement of gout model mice were improved.

[0076] according to Figure 3 It can be seen that the compound of the present invention exhibits the best anti-inflammatory and analgesic effects in terms of improving foot pad swelling and pain threshold.

[0077] according to Figure 4 It can be seen that, in terms of inflammatory factor levels, the compound of this invention has a better inhibitory effect on IL-6 and IL-17A than the Quzhuo Tongbi formula, thus it can play an excellent anti-inflammatory role.

[0078] In summary, the traditional Chinese medicine compound provided in this embodiment contains only 6 herbs, which is simpler than the Quzhuo Tongbi formula (9 herbs), but the efficacy is not reduced and may even be better. This traditional Chinese medicine composition showed a significant uric acid-lowering effect in animal experiments; it can effectively reduce creatinine (CREA), blood urea nitrogen (BUN), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels; at the same time, it alleviates inflammatory responses, reduces serum inflammatory factors IL-1β, IL-6, IFN-γ, and IL-17A levels; significantly improves paw pad swelling and increases pain threshold in gout model mice; and has a protective effect on liver and kidney function.

[0079] In this invention, the terms "one embodiment," "some embodiments," "example," "specific example," or "some examples," etc., refer to a specific feature, structure, material, or characteristic described in connection with that embodiment or example, which is included in at least one embodiment or example of the invention. In this specification, the illustrative expressions of the above terms do not necessarily refer to the same embodiment or example. Furthermore, the specific features, structures, materials, or characteristics described may be combined in any suitable manner in one or more embodiments or examples. Moreover, without contradiction, those skilled in the art can combine and integrate the different embodiments or examples described in this specification, as well as the features of different embodiments or examples.

[0080] Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention. Those skilled in the art can make changes, modifications, substitutions and variations to the above embodiments within the scope of the present invention.

Claims

1. A traditional Chinese medicine composition, characterized in that, Includes or is composed of the following raw materials: Smilax glabra, Dioscorea hypoglauca, corn silk, stir-fried coix seed, Coptis chinensis, and turmeric.

2. The traditional Chinese medicine composition according to claim 1, characterized in that, The raw materials are used to form the traditional Chinese medicine composition in the following parts by weight: 10–20 parts of Smilax glabra; Dioscorea hypoglauca 6–15 parts; 3–10 parts corn silk; 10–20 servings of stir-fried Job's tears; Coptis chinensis 3–10 parts; and Turmeric 6–15 parts.

3. The traditional Chinese medicine composition according to claim 1, characterized in that, The raw materials are used to form the traditional Chinese medicine composition in the following parts by weight: Smilax glabra 12 parts, Dioscorea hypoglauca 9 parts, corn silk 6 parts, stir-fried coix seed 12 parts, Coptis chinensis 6 parts, and turmeric 9 parts.

4. A traditional Chinese medicine preparation, characterized in that, The traditional Chinese medicine preparation includes: The raw material is a raw medicinal powder or its aqueous or organic solvent extract as the active ingredient; and Pharmaceutically acceptable excipients. The ingredients mentioned include Smilax glabra, Dioscorea hypoglauca, corn silk, stir-fried Coix lacryma-jobi, Coptis chinensis, and Curcuma longa, or a combination thereof.

5. The traditional Chinese medicine preparation according to claim 4, characterized in that, The raw materials are composed of the following parts by weight: 10–20 parts of Smilax glabra; Dioscorea hypoglauca 6–15 parts; 3–10 parts corn silk; 10–20 servings of stir-fried Job's tears; Coptis chinensis 3–10 parts; and Turmeric 6–15 parts.

6. The traditional Chinese medicine preparation according to claim 4, characterized in that, The raw materials are composed of the following parts by weight: 12 parts Smilax glabra, 9 parts Dioscorea hypoglauca, 6 parts corn silk, 12 parts stir-fried Coix lacryma-jobi, 6 parts Coptis chinensis, and 9 parts Curcuma longa.

7. The traditional Chinese medicine preparation according to claim 4, characterized in that, The preparations are tablets, capsules, pills, granules, or oral liquids.

8. A method for preparing the traditional Chinese medicine preparation as described in claims 4-6, characterized in that, include: Add water to the traditional Chinese medicine composition as described in any one of claims 1-3 and decoct, wherein the decoction comprises heating over high heat for 40 minutes and then simmering over low heat for 40 minutes. The decoction obtained after boiling is concentrated to obtain a traditional Chinese medicine extract, which is used as the traditional Chinese medicine preparation. Optionally, each portion of the traditional Chinese medicine composition contains 54 g of the total amount, and the volume of the traditional Chinese medicine extract obtained after concentration is approximately 76.9 mL.

9. Use of the traditional Chinese medicine composition as described in any one of claims 1-3 or the traditional Chinese medicine preparation as described in claims 4-6 in the preparation of a medicament for the prevention and / or treatment of gout and / or hyperuricemia.

10. The use according to claim 9, The traditional Chinese medicine composition or preparation improves at least one of the following indicators: Lower CREAM and BUN levels; Lower ALT and AST levels; Reduces the levels of inflammatory factors IL-1β, IL-6, IFN-γ, and IL-17A; Reduce joint swelling; and Increase pain threshold.

Citation Information

Patent Citations

  • Particle for eliminating turbidity and treating arthralgia

    CN101884749B